본문으로 건너뛰기
← 뒤로

Triplet regimens for all: genomically agnostic approaches to improve on HMA + VEN in AML?

1/5 보강
Hematology. American Society of Hematology. Education Program 📖 저널 OA 100% 2022: 1/1 OA 2025: 42/42 OA 2022~2025 2025 Vol.2025(1) p. 607-613
Retraction 확인
출처

Nicol W, Wei AH

📝 환자 설명용 한 줄

Combined hypomethylating agent (HMA) plus venetoclax (Ven) therapy enables most older patients with acute myeloid leukemia (AML) to achieve clinical remission.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Nicol W, Wei AH (2025). Triplet regimens for all: genomically agnostic approaches to improve on HMA + VEN in AML?. Hematology. American Society of Hematology. Education Program, 2025(1), 607-613. https://doi.org/10.1182/hematology.2025000756
MLA Nicol W, et al.. "Triplet regimens for all: genomically agnostic approaches to improve on HMA + VEN in AML?." Hematology. American Society of Hematology. Education Program, vol. 2025, no. 1, 2025, pp. 607-613.
PMID 41348039 ↗

Abstract

Combined hypomethylating agent (HMA) plus venetoclax (Ven) therapy enables most older patients with acute myeloid leukemia (AML) to achieve clinical remission. Key objectives are now aimed at developing new triplet combinations to circumvent mechanisms of resistance and extend remission longevity and, by extension, survival. Genomically agnostic approaches combine hypomethylating agents and venetoclax (HMA-Ven) with novel agents directed at oncogenic pathways critical for leukemic cell survival, proliferation, metabolism, or differentiation. Challenges faced in the development of new HMA-Ven triplets include competition from targeted inhibitors, biological heterogeneity of AML, potential for additive toxicity, reduced efficacy from modifications to the HMA-Ven backbone, and the higher bar for success in older AML beyond the current standard of care.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🟢 PMC 전문 열기